DPP10: Potential Drug Target and Biomarker for Neurological Disorders

Target Name: DPP10

NCBI ID: G57628

DPP10

DPP10: Potential Drug Target and Biomarker for Neurological Disorders

DPP10, also known as DPP10 variant 2, is a protein that is expressed in the brain and has been linked to a number of neurological and psychiatric disorders. The most well-known of these disorders is Alzheimer's disease, which is a degenerative brain disorder that is characterized by the progressive loss of brain cells and the development of aggregates of the protein beta-amyloid.

DPP10 is a transmembrane protein that is expressed in the brain and is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders. It is made up of four structural domains: an N-terminus, a T-terminus, a middle domain, and an C-terminus.

The N-terminus of DPP10 is a 21-amino acid residue that is involved in the interaction with other proteins. The T-terminus of DPP10 is a 24-amino acid residue that is involved in the interaction with the protein p100, which is a neurotransmitter that is involved in the regulation of anxiety and depression. The middle domain of DPP10 is the largest of the four domains and is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders.

DPP10 has been linked to a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It is thought to play a role in the regulation of the neurotransmitter circuitry that is involved in the development and progression of these disorders.

One of the most promising aspects of DPP10 is its potential as a drug target. Because DPP10 is involved in the regulation of various signaling pathways that are involved in the development and progression of neurological and psychiatric disorders, it is a potential target for the development of new treatments for these disorders.

In addition to its potential as a drug target, DPP10 is also a potential biomarker for the diagnosis and progression of neurological and psychiatric disorders. Because it is expressed in the brain and is involved in the regulation of various signaling pathways that are involved in the development and progression of these disorders, it is a potential indicator of the presence of these disorders.

DPP10 is also thought to be involved in the regulation of the immune system, which is a critical part of the body's defense against infection and disease. This suggests that DPP10 may have implications for the development of new treatments for a wide range of disorders, including neurological and psychiatric disorders.

In conclusion, DPP10 is a protein that is expressed in the brain and has been linked to a number of neurological and psychiatric disorders. The most well-known of these disorders is Alzheimer's disease, but DPP10 is also thought to be involved in the regulation of various signaling pathways that are involved in the development and progression of these disorders. As a result, DPP10 is a potential drug target and a potential biomarker for the diagnosis and progression of these disorders. Further research is needed to fully understand the role of DPP10 in the regulation of the brain and the development and progression of neurological and psychiatric disorders.

Protein Name: Dipeptidyl Peptidase Like 10

Functions: Promotes cell surface expression of the potassium channel KCND2 (PubMed:15454437). Modulates the activity and gating characteristics of the potassium channel KCND2 (PubMed:15454437). Has no dipeptidyl aminopeptidase activity (PubMed:12662155)

The "DPP10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPP10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets